Skip to main content
. 2018 Feb 3;57(5):900–908. doi: 10.1093/rheumatology/kex489

Fig. 4.

Fig. 4

Percentage of patients achieving CDAI ≤10 at week 12: subgroups defined by previous bDMARD experience

Data (non-responder imputation) are presented as n/N (%). ADA: adalimumab; ETN: etanercept; INFLIX: infliximab; N: number of patients in the specified subgroup; n: number of patients in the specified category; NA: interaction analysis not applicable.